menu search

Intellia: in-vivo gene editing platform continues to deliver

In-vivo CRISPR/Cas9 knock out gene editing treatments NTLA-2002 and NTLA-2001 have established proof of concept in treating patients with HAE and ATTR...

December 20, 2022, 8:25 am

Amcor: strong supplier of packaging for leading brands

Amcor is an Australian-based company that supplies packaging materials for various industries to major brands such as Unilever, Nestle, Mondelez, Peps...

December 19, 2022, 5:32 am

Harrow health transaction moves it closer to the big leagues for 2023

Harrow Health is a founder-led eyecare company, the CEO holds 10% of the shares. It is moving up the value chain with a focus on branded products such...

December 15, 2022, 4:47 am

Harrow health forges agreement to acquire exclusive us rights to blockbuster novartis eyecare drugs

Harrow Health Inc (NASDAQ:HROW) revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food...

December 14, 2022, 12:07 pm

Clovis enters bankruptcy with deal to sell cancer-drug candidate to novartis

Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a ...

December 12, 2022, 2:05 pm

Clovis (clvs) files for bankruptcy amid lack of financial aid

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with ...

December 12, 2022, 12:02 pm

novartis prostate cancer drug trial meets primary endpoint

novartis AG said Monday that a trial to evaluate prostate-cancer drug Pluvicto met its primary endpoint...

December 5, 2022, 1:44 am

novartis (nvs) set to advance malaria drug into phase iii

novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of pa...

November 24, 2022, 12:02 pm

C-suite shakeup pressures teva pharmaceutical stock

Teva Pharmaceutical Industries Ltd  (NYSE:TEVA) is down 2.1% at $8.54 at last check, after the company named former ...

November 21, 2022, 10:49 am

novartis: limited growth

We analyzed the latest Pharma conference with key takeaways on the Inflation Reduction Act development and the company's reorganization. Limited growt...

November 15, 2022, 4:43 pm

novartis taps msd exec marshall to replace bradner as research head

novartis appointed Merck executive Fiona Marshall as president of the ...

September 1, 2022, 1:17 am

novartis looks appealing, based on strong drug pipeline and planned sandoz spinoff

These reports, excerpted and edited by Barron's, were issued recently by investment and research firms. The reports are a sampling of analysts' thinki...

August 26, 2022, 6:25 pm

Analysis-novartis ceo may struggle to rally investors to sandoz spin-off

novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business S...

August 26, 2022, 1:11 am

Sandoz will be a long-term stable business if it can get its cost structure right, novasecta says

John Rountree, managing partner at pharma consultancy Novasecta, discusses novartis' decision to spin o...

August 25, 2022, 6:28 am

novartis to spin off, list sandoz business

novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as a stand...

August 25, 2022, 1:53 am

novartis to spin off sandoz, list it in zurich

novartis said on Thursday it would spin off Sandoz and list it on the Swiss stock exchange to create th...

August 25, 2022, 1:23 am

novartis: undervalued swiss pharma giant

novartis is a global healthcare company with a research-driven focus on pharmaceuticals, both prescript...

August 21, 2022, 3:51 am

Valeo pharma enters commercialization and supply agreement with novartis canada for two ophthalmic therapies

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it has entered into a commercialization and supply agreement with ...

August 2, 2022, 8:01 am

novartis (nvs) q2 earnings beat, revenues miss estimates

novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic...

July 19, 2022, 12:23 pm

novartis posts mixed q2 earnings, expects improved earnings at sandoz

novartis AG (NYSE: NVS) has reported a core EPS of $1.56 in Q2 FY22 compared to $1.66 a year ago, be...

July 19, 2022, 6:08 am


Search within

Pages Search Results: